Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure - Ahmed, Ahmed T; Biernacka, Joanna M; Jenkins, Gregory; Rush, A John; Shinozaki, Gen; Veldic, Marin; Kung, Simon; Bobo, William V; Hall-Flavin, Daniel K; Weinshilboum, Richard M; Wang, Liewei; Frye, Mark A (Journal of affective disorders, 2019)
Keywords: Adult; Antidepressive Agents - pharmacokinetics; Antidepressive Agents - therapeutic use; Citalopram - therapeutic use; CYP2D6; Cytochrome P-450 CYP2C19 - metabolism; Cytochrome P-450 CYP2D6 - metabolism; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - genetics; Depressive Disorder, Major - metabolism; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins - genetics; Pharmacodynamic-pharmacokinetic interaction; Phenotype; Psychiatric/Mental Health; Remission; Serotonin Plasma Membrane Transport Proteins - genetics; Serotonin Uptake Inhibitors - pharmacokinetics; Serotonin Uptake Inhibitors - therapeutic use; SLC6A2; SLC6A4; Treatment Failure; Venlafaxine Hydrochloride - pharmacokinetics; Venlafaxine Hydrochloride - therapeutic use; Venlafaxine-XR; Pharmacodynamic-pharmacokinetic interaction; Remission; Venlafaxine-XR; CYP2D6; SLC6A2; SLC6A4